Tivdak Approved for Recurrent or Metastatic Cervical Cancer
Cervical Cancer General Gynecologic Cancers News Obstetrics and Gynecology Oncology

Tivdak Approved for Recurrent or Metastatic Cervical Cancer

The Food and Drug Administration has granted accelerated approval to Tivdak (tisotumab vedotin-tftv) for the treatment of adults with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.  Tivdak is a tissue…